Soligenix, Inc.’s common stock is listed on Nasdaq under the symbol SNGX. Stockholders and interested parties are urged to contact our main office in Princeton, New Jersey at 609-538-8200 or send an e-mail to firstname.lastname@example.org for further information.
- February 8, 2017: View the presentation on YouTube / View the presentation PDF
- December 16, 2016: View the Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis Webcast on YouTube
- August 2016: View the Dusquetide (SGX94) TechWatch Presentation on YouTube / View the presentation PDF
Financial and Corporate Governance Information
- Soligenix Stock Quote (Website link)
- Soligenix Filings with the SEC (Website link)
- Code of Ethics
- Audit Committee Charter (PDF)
- Compensation Committee Charter (PDF)
- Nominating Committee Charter (PDF)
- Director Compensation and Stock Ownership Policy (PDF)
If you would like to receive our Investor Relations Packet, including reprints of scientific publications relating to our products, click here. Thank you for your interest.